The role of EZH2 in tumour progression - PubMed (original) (raw)

Review

. 2012 Jan 17;106(2):243-7.

doi: 10.1038/bjc.2011.551. Epub 2011 Dec 20.

Affiliations

• PMID: 22187039
• PMCID: PMC3261672
• DOI: 10.1038/bjc.2011.551

Review

The role of EZH2 in tumour progression

C-J Chang et al. Br J Cancer. 2012.

Abstract

Accumulated evidence shows that EZH2 is deregulated in a wide range of cancer types, and it has a crucial role in stem cell maintenance and tumour development. Therefore, blocking EZH2 expression or activity may represent a promising strategy for anticancer treatment. In this review, we address the current understanding of the mechanisms underlying EZH2 regulation alongside the function of EZH2 gene targets that are involved in cancer progression. Finally, we will describe cancer therapies that target EZH2 or its downstream cascades, which could potentially reverse the oncogenic and stemness properties of the tumour cells to suppress cancer progression and recurrence.

PubMed Disclaimer

Similar articles

• Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
  Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, Kapetis D, Marras C, Schiffer D, Finocchiaro G. Orzan F, et al. Neuropathol Appl Neurobiol. 2011 Jun;37(4):381-94. doi: 10.1111/j.1365-2990.2010.01132.x. Neuropathol Appl Neurobiol. 2011. PMID: 20946108
• Epigenetic control of hematopoietic stem cell aging the case of Ezh2.
  De Haan G, Gerrits A. De Haan G, et al. Ann N Y Acad Sci. 2007 Jun;1106:233-9. doi: 10.1196/annals.1392.008. Epub 2007 Mar 1. Ann N Y Acad Sci. 2007. PMID: 17332078 Review.
• The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
  Zeidler M, Kleer CG. Zeidler M, et al. J Mol Histol. 2006 Sep;37(5-7):219-23. doi: 10.1007/s10735-006-9042-9. Epub 2006 Jul 20. J Mol Histol. 2006. PMID: 16855786 Review.
• Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.
  Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, Koseki H, Iwama A. Tanaka S, et al. Blood. 2012 Aug 2;120(5):1107-17. doi: 10.1182/blood-2011-11-394932. Epub 2012 Jun 7. Blood. 2012. PMID: 22677129
• EZH2 methyltransferase and H3K27 methylation in breast cancer.
  Yoo KH, Hennighausen L. Yoo KH, et al. Int J Biol Sci. 2012;8(1):59-65. doi: 10.7150/ijbs.8.59. Epub 2011 Nov 18. Int J Biol Sci. 2012. PMID: 22211105 Free PMC article. Review.

Cited by

• Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities.
  Zhang J, Zeng X, Guo Q, Sheng Z, Chen Y, Wan S, Zhang L, Zhang P. Zhang J, et al. Exp Hematol Oncol. 2024 Aug 5;13(1):78. doi: 10.1186/s40164-024-00548-w. Exp Hematol Oncol. 2024. PMID: 39103941 Free PMC article. Review.
• EZH2 Expression in Head-and-Neck Squamous Cell Cancer in Young Patients.
  Révész M, Oberna F, Slezák A, Tóth E, Ferenczi Ö, Kenessey I, Takácsi-Nagy Z. Révész M, et al. Int J Mol Sci. 2024 May 11;25(10):5250. doi: 10.3390/ijms25105250. Int J Mol Sci. 2024. PMID: 38791289 Free PMC article.
• Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance.
  Xu D, Wang W, Wang D, Ding J, Zhou Y, Zhang W. Xu D, et al. Noncoding RNA Res. 2024 Feb 1;9(2):388-406. doi: 10.1016/j.ncrna.2024.01.015. eCollection 2024 Jun. Noncoding RNA Res. 2024. PMID: 38511067 Free PMC article. Review.
• Enhancer of zeste homolog 2 facilitates phenotypic transition of vascular smooth muscle cells leading to aortic aneurysm/dissection.
  Xue S, Leng S, Zhang F, Dang Z, Su G, Yu W. Xue S, et al. Exp Ther Med. 2024 Feb 19;27(4):145. doi: 10.3892/etm.2024.12433. eCollection 2024 Apr. Exp Ther Med. 2024. PMID: 38476905 Free PMC article.
• A methylation-phosphorylation switch controls EZH2 stability and hematopoiesis.
  Guo P, Lim RC, Rajawasam K, Trinh T, Sun H, Zhang H. Guo P, et al. Elife. 2024 Feb 12;13:e86168. doi: 10.7554/eLife.86168. Elife. 2024. PMID: 38346162 Free PMC article.

References

1. 1. Abdel-Wahab O, Levine RL (2010) EZH2 mutations: mutating the epigenetic machinery in myeloid malignancies. Cancer Cell 18: 105–107
2. 1. Boukarabila H, Saurin AJ, Batsche E, Mossadegh N, van Lohuizen M, Otte AP, Pradel J, Muchardt C, Sieweke M, Duprez E (2009) The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev 23: 1195–1206 - PMC - PubMed
3. 1. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323–5335 - PMC - PubMed
4. 1. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Kleer CG, Varambally S, Chinnaiyan AM (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274–7284 - PMC - PubMed
5. 1. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, Ping B, Otte AP, Hung MC (2005) Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310: 306–310 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations